Ongoing treatment with anti-vascular endothelial growth factor (VEGF) injections or photodynamic therapy (verteporfin) is, to date, the primary means of managing and treating AMD.
With no “cure,” neovascular age-related macular degeneration (or wet AMD) remains a key disease state for numerous pharmaceutical companies.
About 85% to 90% of the cases of age-related macular degeneration (AMD) are the “dry” (atrophic) type.
The year 2018 had its share of groundbreaking research in age-related macular degeneration (AMD). Here is a brief overview of what’s been presented or published within the past 12 months.
More and more companies are looking for novel ways to educate both eye-care professionals and patients about age-related macular degeneration (AMD).
Below are a few of the newer training materials available.
Age-related macular degeneration (AMD) affects more than 10 million Americans, and the risk of developing AMD is increased when there is a family history.
A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration (AMD), according to a study.1
Numerous websites are designed to raise awareness about age-related macular degeneration (AMD), some sponsored by the National Eye Institute, others by disease-specific foundations, and others by industry.
Clinical trial data focusing on treatment for age-related macular degeneration (AMD) have been a highlight at many recent ophthalmology meetings. Here are a few of the latest clinical trials that physicians need to be aware.
Although a proven treatment therapy, age-related macular degeneration (AMD) requires frequent, costly anti-vascular endothelial growth factor (anti-VEGF) injections. Some pharmaceutical companies do have patient-assistance programs to help alleviate the financial burden.